2026 · 3rd Quarter (July 1 - Sep 30)

CHATTEM, INC. DBA OPELLA

Filed by AKIN GUMP STRAUSS HAUER & FELD.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2026
Income: $70,000.00
Expenses: Not reported
Registrant: AKIN GUMP STRAUSS HAUER & FELD
Client: CHATTEM, INC. DBA OPELLA
Filing UUID: 4041f904-e435-4089-88dd-f0d34f951ab4
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).

Literal federal measure citations: H.R. 9393, H.R. 8646, H.R. 8495, H.R. 7602, S. 5113, S. 3788, H.R. 8269

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.